Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 6/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29103977 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2LMNAMAPK1HPGDCES2 | |
| SCHEMBL1174179 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2LMNAMAPK1HPGDCES2 | |
| SCHEMBL353571 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNAMAPK1HPGDCES2 | |
| SCHEMBL3726123 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNAMAPK1HPGDMEN1 | |
| SCHEMBL16644926 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNAHPGDMEN1KMT2A | |
| SCHEMBL21535462 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2LMNAHPGDMEN1KMT2A | |
| SCHEMBL11480577 | 0.80 | GLI1 (0.47) | SMN1; SMN2LMNAMEN1KMT2ACHRM2 | |
| SCHEMBL354777 | 0.79 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNAHPGDMEN1KMT2A | |
| SCHEMBL9019184 | 0.79 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNAHPGDMEN1KMT2A | |
| SCHEMBL4991700 | 0.79 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNAHPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117003665-A | Synthesis process of N, N-diethyl-2-hydroxy-2-phenylacetamide | 百新(北京)药业科技有限责任公司 | 2023-11-07 | — | — | CN | claimed |
| CN-117003665-A | Synthesis process of N, N-diethyl-2-hydroxy-2-phenylacetamide | 百新(北京)药业科技有限责任公司 | 2023-11-07 | — | — | CN | disclosed |
| US-8338426-B2 | Piperazinyl derivatives useful as modulators of the neuropeptide Y2 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2012-12-25 | — | — | US | disclosed |
| US-8338426-B2 | Piperazinyl derivatives useful as modulators of the neuropeptide Y2 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2012-12-25 | — | — | US | disclosed |
| US-8338426-B2 | Piperazinyl derivatives useful as modulators of the neuropeptide Y2 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2012-12-25 | — | — | US | disclosed |
| US-20110046151-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046151-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046151-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-24 | — | — | US | disclosed |
| WO-2009006185-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009006185-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046151-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NPY2R, NPY1R, NPY5R | SMN1; SMN2 3067/4885LMNA 3601/4885MAPK1 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.